Roivant Sciences Ltd. (ROIV) Stock Ticker
ROIV right now
Market factors today
Unlock the full ROIV picture
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV stock facts
| Ticker symbol | ROIV |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $25.9B |
| CEO | Matthew Gline |
| Employees | 721 |
| Headquarters | London, GL, GB |
| IPO date | 2020-12-08 |
| Website | roivant.com |
What you can see for ROIV on Tickr
Live ROIV price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ROIV report.
Rankings
FAQ
What is the ticker symbol for Roivant Sciences Ltd.?
The ticker symbol for Roivant Sciences Ltd. is ROIV, listed on the NASDAQ Global Market.
What is ROIV?
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare…